• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Akt 抑制增强了芹菜素联合 PLX4032 在携带 BRAFV600E 的间变性甲状腺癌细胞中的细胞毒性作用。

Akt inhibition enhances the cytotoxic effect of apigenin in combination with PLX4032 in anaplastic thyroid carcinoma cells harboring BRAFV600E.

机构信息

Division of Endocrinology and Metabolism, Department of Internal Medicine, College of Medicine, Hallym University, Chuncheon 200-704, Republic of Korea.

出版信息

J Endocrinol Invest. 2013 Dec;36(11):1099-104. doi: 10.3275/9099. Epub 2013 Sep 27.

DOI:10.3275/9099
PMID:24084189
Abstract

Aim of the present study was to evaluate the effect of apigenin in combination with BRAFV600E inhibitor PLX4032 on cell survival, and to investigate the influence of Akt inhibition on the combined effect of apigenin and PLX4032 in ATC cells harboring BRAFV600E. In 8505C and FRO cells harboring BRAFV600E, after treatment of apigenin and PLX4032, the cell viability decreased, and the percentage of dead cells increased in a time- and concentration-dependent manner, respectively. In apigenin- and PLX4032- treated cells, compared with apigenin alone-treated cells, the cell viability was lessened, and the percentage of dead cells was multiplied. In the addition of PLX4032 to apigenin, compared with the treatment of apigenin alone, the protein levels of cleaved PARP-1 and cleaved caspase-3 were elevated, and phospho-ERK protein levels were reduced, and the protein levels of total ERK, c-Myc, BRAF, phospho-Akt, phospho-p70S6K and phospho-4EBP1 were not varied. Compared with the treatment of PLX4032 alone, phosphop70S6K protein levels were reduced, and the other protein levels were not altered. Phospho-ERK protein levels were reduced only in 8505C cells. Under the co-treatment of apigenin and PLX4032, administration of the PI3K inhibitor wortmannin further decreased the cell viability, and increased the percentage of dead cells. In conclusion, our results suggest that PLX4032 augments apigenin-induced cytotoxicity in ATC cells harboring BRAFV600E. Moreover, Akt suppression potentiates the combined effect of apigenin and PLX4032 in ATC cells harboring BRAFV600E.

摘要

本研究旨在评估芹菜素联合 BRAFV600E 抑制剂 PLX4032 对细胞存活的影响,并研究 Akt 抑制对 BRAFV600E 阳性 ATC 细胞中芹菜素和 PLX4032 联合作用的影响。在携带 BRAFV600E 的 8505C 和 FRO 细胞中,芹菜素和 PLX4032 处理后,细胞活力呈时间和浓度依赖性下降,死亡细胞比例增加。在芹菜素和 PLX4032 处理的细胞中,与单独用芹菜素处理的细胞相比,细胞活力降低,死亡细胞比例增加。在添加 PLX4032 到芹菜素中,与单独用芹菜素处理相比,裂解的 PARP-1 和裂解的 caspase-3 蛋白水平升高,磷酸化 ERK 蛋白水平降低,总 ERK、c-Myc、BRAF、磷酸化 Akt、磷酸化 p70S6K 和磷酸化 4EBP1 蛋白水平没有变化。与单独用 PLX4032 处理相比,磷酸化 p70S6K 蛋白水平降低,其他蛋白水平没有改变。只有在 8505C 细胞中,磷酸化 ERK 蛋白水平降低。在芹菜素和 PLX4032 的共同处理下,给予 PI3K 抑制剂wortmannin 进一步降低了细胞活力,增加了死亡细胞的比例。综上所述,我们的结果表明,PLX4032 增强了 BRAFV600E 阳性 ATC 细胞中芹菜素诱导的细胞毒性。此外,Akt 抑制增强了 BRAFV600E 阳性 ATC 细胞中芹菜素和 PLX4032 的联合作用。

相似文献

1
Akt inhibition enhances the cytotoxic effect of apigenin in combination with PLX4032 in anaplastic thyroid carcinoma cells harboring BRAFV600E.Akt 抑制增强了芹菜素联合 PLX4032 在携带 BRAFV600E 的间变性甲状腺癌细胞中的细胞毒性作用。
J Endocrinol Invest. 2013 Dec;36(11):1099-104. doi: 10.3275/9099. Epub 2013 Sep 27.
2
The MEK1/2 Inhibitor AZD6244 Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib.MEK1/2 抑制剂 AZD6244 增敏 BRAF 突变型甲状腺癌对威罗菲尼的敏感性。
Med Sci Monit. 2018 May 8;24:3002-3010. doi: 10.12659/MSM.910084.
3
S100A4 Knockout Sensitizes Anaplastic Thyroid Carcinoma Cells Harboring BRAFV600E/Mt to Vemurafenib.S100A4基因敲除使携带BRAFV600E/Mt的间变性甲状腺癌细胞对维莫非尼敏感。
Cell Physiol Biochem. 2018;49(3):1143-1162. doi: 10.1159/000493296. Epub 2018 Sep 7.
4
Inhibition of p21 and Akt potentiates SU6656-induced caspase-independent cell death in FRO anaplastic thyroid carcinoma cells.抑制 p21 和 Akt 可增强 SU6656 诱导的 FRO 间变性甲状腺癌细胞中的 caspase 非依赖性细胞死亡。
Horm Metab Res. 2013 Jun;45(6):408-14. doi: 10.1055/s-0033-1333716. Epub 2013 Feb 5.
5
Suppression of AKT Potentiates Synergistic Cytotoxicity of Apigenin with TRAIL in Anaplastic Thyroid Carcinoma Cells.抑制AKT增强芹菜素与TRAIL在间变性甲状腺癌细胞中的协同细胞毒性。
Anticancer Res. 2015 Dec;35(12):6529-37.
6
The Akt inhibitor MK2206 synergizes, but perifosine antagonizes, the BRAF(V600E) inhibitor PLX4032 and the MEK1/2 inhibitor AZD6244 in the inhibition of thyroid cancer cells.Akt 抑制剂 MK2206 与 BRAF(V600E)抑制剂 PLX4032 和 MEK1/2 抑制剂 AZD6244 协同抑制甲状腺癌细胞,但 perifosine 则拮抗其作用。
J Clin Endocrinol Metab. 2012 Feb;97(2):E173-82. doi: 10.1210/jc.2011-1054. Epub 2011 Nov 16.
7
Tunicamycin induces paraptosis potentiated by inhibition of BRAFV600E in FRO anaplastic thyroid carcinoma cells.豚草霉素诱导 BRAFV600E 抑制的 FRO 间变性甲状腺癌细胞发生 Paraptosis。
Anticancer Res. 2014 Sep;34(9):4857-68.
8
c-Met-mediated reactivation of PI3K/AKT signaling contributes to insensitivity of BRAF(V600E) mutant thyroid cancer to BRAF inhibition.c-Met介导的PI3K/AKT信号通路重新激活导致BRAF(V600E)突变型甲状腺癌对BRAF抑制不敏感。
Mol Carcinog. 2016 Nov;55(11):1678-1687. doi: 10.1002/mc.22418. Epub 2015 Oct 12.
9
Combinatorial treatments that overcome PDGFRβ-driven resistance of melanoma cells to V600EB-RAF inhibition.联合治疗方案可克服黑色素瘤细胞对 V600EB-RAF 抑制的 PDGFRβ 驱动耐药性。
Cancer Res. 2011 Aug 1;71(15):5067-74. doi: 10.1158/0008-5472.CAN-11-0140.
10
The BRAFT1799A mutation confers sensitivity of thyroid cancer cells to the BRAFV600E inhibitor PLX4032 (RG7204).BRAFT1799A 突变使甲状腺癌细胞对 BRAFV600E 抑制剂 PLX4032(RG7204)敏感。
Biochem Biophys Res Commun. 2011 Jan 28;404(4):958-62. doi: 10.1016/j.bbrc.2010.12.088. Epub 2010 Dec 23.

引用本文的文献

1
Anaplastic thyroid cancer: Genetic roles, targeted therapy, and immunotherapy.间变性甲状腺癌:基因作用、靶向治疗及免疫治疗
Genes Dis. 2024 Aug 30;12(4):101403. doi: 10.1016/j.gendis.2024.101403. eCollection 2025 Jul.
2
Anticancer effects of natural phytochemicals in anaplastic thyroid cancer (Review).天然植物化学物质在间变性甲状腺癌中的抗癌作用(综述)。
Oncol Rep. 2022 Sep;48(3). doi: 10.3892/or.2022.8368. Epub 2022 Jul 20.
3
Anticancer Effects and Molecular Mechanisms of Apigenin in Cervical Cancer Cells.芹菜素对宫颈癌细胞的抗癌作用及分子机制

本文引用的文献

1
BRAF V600E inhibition in anaplastic thyroid cancer.BRAF V600E 抑制在间变性甲状腺癌中的作用
N Engl J Med. 2013 Feb 14;368(7):684-5. doi: 10.1056/NEJMc1215697.
2
Inhibition of p21 and Akt potentiates SU6656-induced caspase-independent cell death in FRO anaplastic thyroid carcinoma cells.抑制 p21 和 Akt 可增强 SU6656 诱导的 FRO 间变性甲状腺癌细胞中的 caspase 非依赖性细胞死亡。
Horm Metab Res. 2013 Jun;45(6):408-14. doi: 10.1055/s-0033-1333716. Epub 2013 Feb 5.
3
Apigenin induces c-Myc-mediated apoptosis in FRO anaplastic thyroid carcinoma cells.
Cancers (Basel). 2022 Apr 4;14(7):1824. doi: 10.3390/cancers14071824.
4
Exploring the Natural Compounds in Flavonoids for Their Potential Inhibition of Cancer Therapeutic Target MEK1 Using Computational Methods.利用计算方法探索黄酮类化合物中的天然化合物对癌症治疗靶点MEK1的潜在抑制作用。
Pharmaceuticals (Basel). 2022 Feb 3;15(2):195. doi: 10.3390/ph15020195.
5
Combinatorial Therapies in Thyroid Cancer: An Overview of Preclinical and Clinical Progresses.甲状腺癌的联合治疗:临床前和临床进展概述。
Cells. 2020 Mar 30;9(4):830. doi: 10.3390/cells9040830.
6
Evodiamine in combination with histone deacetylase inhibitors has synergistic cytotoxicity in thyroid carcinoma cells.表小檗碱联合组蛋白去乙酰化酶抑制剂对甲状腺癌细胞具有协同细胞毒性。
Endocrine. 2019 Jul;65(1):110-120. doi: 10.1007/s12020-019-01885-1. Epub 2019 May 17.
7
Synergistic cytotoxicity of the dipeptidyl peptidase-IV inhibitor gemigliptin with metformin in thyroid carcinoma cells.二肽基肽酶-4 抑制剂 gemigliptin 与二甲双胍在甲状腺癌细胞中的协同细胞毒性作用。
Endocrine. 2018 Feb;59(2):383-394. doi: 10.1007/s12020-017-1503-2. Epub 2017 Dec 28.
8
Gemigliptin, a novel dipeptidyl peptidase-IV inhibitor, exerts a synergistic cytotoxicity with the histone deacetylase inhibitor PXD101 in thyroid carcinoma cells.二甲双胍,一种新型的二肽基肽酶-4 抑制剂,与组蛋白去乙酰化酶抑制剂 PXD101 在甲状腺癌细胞中具有协同细胞毒性作用。
J Endocrinol Invest. 2018 Jun;41(6):677-689. doi: 10.1007/s40618-017-0792-x. Epub 2017 Nov 16.
9
Correlative Studies in Clinical Trials: A Position Statement From the International Thyroid Oncology Group.临床试验中的相关性研究:国际甲状腺肿瘤学组的立场声明
J Clin Endocrinol Metab. 2015 Dec;100(12):4387-95. doi: 10.1210/jc.2015-2818. Epub 2015 Sep 29.
10
Apigenin in combination with Akt inhibition significantly enhances thyrotropin-stimulated radioiodide accumulation in thyroid cells.芹菜素与Akt抑制联合使用可显著增强促甲状腺激素刺激的甲状腺细胞放射性碘摄取。
Thyroid. 2014 May;24(5):878-87. doi: 10.1089/thy.2013.0614. Epub 2014 Mar 6.
芹菜素诱导 FRO 间变性甲状腺癌细胞中 c-Myc 介导的细胞凋亡。
Mol Cell Endocrinol. 2013 Apr 30;369(1-2):130-9. doi: 10.1016/j.mce.2013.01.012. Epub 2013 Jan 29.
4
Target therapies for radioiodine refractory advanced thyroid tumors.用于治疗放射性碘难治性晚期甲状腺肿瘤的靶向治疗药物。
J Endocrinol Invest. 2012;35(6 Suppl):40-4.
5
CCAAT/Enhancer-binding protein-homologous protein sensitizes to SU5416 by modulating p21 and PI3K/Akt signal pathway in FRO anaplastic thyroid carcinoma cells.CCAAT/增强子结合蛋白同源蛋白通过调节 FRO 间变性甲状腺癌细胞中的 p21 和 PI3K/Akt 信号通路对 SU5416 敏感。
Horm Metab Res. 2013 Jan;45(1):9-14. doi: 10.1055/s-0032-1323680. Epub 2012 Aug 23.
6
BRAFV600E negatively regulates the AKT pathway in melanoma cell lines.BRAFV600E 负向调节黑色素瘤细胞系中的 AKT 通路。
PLoS One. 2012;7(8):e42598. doi: 10.1371/journal.pone.0042598. Epub 2012 Aug 3.
7
Late intervention with anti-BRAF(V600E) therapy induces tumor regression in an orthotopic mouse model of human anaplastic thyroid cancer.晚期应用抗 BRAF(V600E)治疗可诱导人甲状腺未分化癌原位小鼠模型中的肿瘤消退。
Endocrinology. 2012 Feb;153(2):985-94. doi: 10.1210/en.2011-1519. Epub 2011 Dec 27.
8
Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.BRAF 抑制剂 vemurafenib 在 BRAF 突变型结直肠癌的临床前模型中的抗肿瘤活性。
Cancer Res. 2012 Feb 1;72(3):779-89. doi: 10.1158/0008-5472.CAN-11-2941. Epub 2011 Dec 16.
9
The Akt inhibitor MK2206 synergizes, but perifosine antagonizes, the BRAF(V600E) inhibitor PLX4032 and the MEK1/2 inhibitor AZD6244 in the inhibition of thyroid cancer cells.Akt 抑制剂 MK2206 与 BRAF(V600E)抑制剂 PLX4032 和 MEK1/2 抑制剂 AZD6244 协同抑制甲状腺癌细胞,但 perifosine 则拮抗其作用。
J Clin Endocrinol Metab. 2012 Feb;97(2):E173-82. doi: 10.1210/jc.2011-1054. Epub 2011 Nov 16.
10
Prognostic factors and treatment outcomes of 100 cases of anaplastic thyroid carcinoma.100 例间变性甲状腺癌的预后因素和治疗结果。
Thyroid. 2011 Nov;21(11):1183-9. doi: 10.1089/thy.2010.0332. Epub 2011 Sep 21.